Viking Therapeutics (VKTX) Chief Commercial Officer reports no share ownership on Form 3

Rhea-AI Filing Summary

Viking Therapeutics, Inc. filed an initial insider ownership report for its Chief Commercial Officer, Neil William Aubuchon, on a Form 3. The filing states that, at the time of this report, he does not beneficially own any Viking Therapeutics securities, either directly or indirectly. This is a standard disclosure required when an individual becomes an officer of a public company and establishes a baseline of reported ownership going forward.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Aubuchon Neil William

(Last) (First) (Middle)

9920 PACIFIC HEIGHTS BLVD

SUITE 350

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/12/2026

3. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Michael Morneau, as Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Viking Therapeutics (VKTX) Form 3 filing for Neil William Aubuchon show?

The Form 3 for Viking Therapeutics (VKTX) reports that Chief Commercial Officer Neil William Aubuchon currently beneficially owns no securities of the company.

Who is the insider named in this Viking Therapeutics (VKTX) Form 3?

The insider is Neil William Aubuchon, who serves as Chief Commercial Officer of Viking Therapeutics.

Does the Viking Therapeutics (VKTX) Chief Commercial Officer own any company shares according to this Form 3?

According to the Form 3, the Chief Commercial Officer does not beneficially own any Viking Therapeutics securities as of the reported date.

Why did Viking Therapeutics (VKTX) file a Form 3 for its Chief Commercial Officer?

Form 3 is required when someone becomes an officer, director, or large shareholder, and this filing records the initial beneficial ownership status of the Chief Commercial Officer.

Are there any transactions reported in this Viking Therapeutics (VKTX) Form 3?

No transactions are reported. The filing simply states that no securities are beneficially owned by the reporting person.